CLSTN3

Across TCGA pan-cancer cohorts, CLSTN3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLSTN3 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLSTN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CLSTN3 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and GBM are the cancer types where CLSTN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.270	0.539	.008	21	view →
CCRCC	DFS	Quartile	II,III,IV	0.140	0.830	.038	6	view →
GBM	OS	Quartile	All	0.247	0.570	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLSTN3–PDAC (OS)

Open the PDAC breakdown →